2021 Annual Global Meeting: Virtual-Plenary I: Oral Abstract Presentation

Video Transcription

Video Summary

The 2021 Annual Global Meeting of the International Gynecologic Cancer Society (IGCS) was held virtually due to the COVID-19 pandemic. The meeting aimed to provide an opportunity for experts in gynecologic cancer to share scientific and educational content. The opening ceremony featured speeches from various individuals, including the IGCS Council, program chairs, and industry partners.<br /><br />The first speaker, Dr. Krishnansu Tewari, presented the results of a phase three trial of Simplimumab, a monoclonal antibody, versus chemotherapy in patients with recurrent and metastatic cervical carcinoma. The trial showed that Simplimumab improved overall survival compared to chemotherapy, particularly in patients with squamous cell carcinoma. The safety profile of Simplimumab was also favorable.<br /><br />The second speaker, Dr. Vicky Mocker, presented data from the Keynote 775 trial, which investigated the combination of Lenvatinib, a tyrosine kinase inhibitor, and Pembrolizumab, a checkpoint inhibitor, in advanced endometrial cancer. The trial showed significant improvements in progression-free survival and overall survival with the combination therapy compared to treatment of physician's choice.<br /><br />The third speaker, Dr. Anna Ochten, presented data from the Garnet study, which evaluated the activity of Dostarlimab, a checkpoint inhibitor, in patients with advanced or recurrent endometrial cancer. The study showed durable anti-tumor activity in both mismatch repair-deficient and proficient patients, with higher response rates observed in those with one prior line of therapy.<br /><br />Overall, the presented studies demonstrated the efficacy and safety of checkpoint inhibitors and combination therapies in gynecologic cancers. These findings have the potential to change clinical practice and provide new treatment options for patients with advanced or recurrent disease.

Keywords

IGCS

virtual meeting

Simplimumab

chemotherapy

squamous cell carcinoma

Keynote 775 trial

Lenvatinib

Pembrolizumab